ArticleScientific reports2025
Decoding the multifaceted cellular and transcriptomic variations of natural killer cells generated from patients with Parkinson's disease.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Shared gene signatures and biochemical regulatory networks linking Parkinson's disease and ulcerative colitis.NPJ Parkinson's disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Parkinson's disease (PD) is an intractable progressive neurodegenerative disease with poor prognosis in elder patients, which is largely attribute to the deficiency of ultimate pathogenesis. Longitudinal studies have indicated a pivotal role of natural killer (NK) cells, yet the systematic and detailed information of circulating NK cells in PD is largely unknowable. To explore the role of NK cells in PD, we isolated mononuclear cells from peripheral blood (PBMCs) by Ficoll-based density gradient centrifugation, and detected the content of total resident NK cells in healthy donors (HD-NKs) and PD patients (PD-NKs) and the concomitant subsets by flow cytometry (FCM) assay. Then, we took advantage of our well-established "3ILs"-based strategy for ex vivo NK cell expansion and activation, and followed by cellular viability and cytotoxicity assessment. By conducting RNA-sequencing (RNA-SEQ) and multifaceted bioinformatics analyses, we compared the transcriptomic signatures of expanded HD-NKs and PD-NKs. Compared to HD-NKs, PD-NKs showed increase in resident NK cells but minimal differences in expanded NK cells, together with diversity in the subpopulations of NK cells (CD16
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.